Form 6-K Chemomab Therapeutics For: May 14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2026

 

Commission File Number 001-38807

 

CHEMOMAB THERAPEUTICS LTD.
(Translation of registrant’s name into English)

 

10 Habarzel Street, Building C, 10th Floor, Tel-Aviv, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

EXPLANATORY NOTE

 

On May 14, 2026, Chemomab Therapeutics Ltd. (the “Registrant”) issued a press release titled “Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update”, a copy of which is furnished as Exhibit 99.1 herewith.

 

The financial information included in the consolidated balance sheets and consolidated statements of operations contained in the press release attached as Exhibit 99.1 to this Report on Form 6-K is hereby incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-275002 and 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).

Exhibit	Description
99.1	Press release, dated May 14, 2026, titled “Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update”

	CHEMOMAB THERAPEUTICS LTD.
Date: May 14, 2026	By:	/s/ Sigal Fattal
		Sigal Fattal
		Chief Financial Officer